Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Northwell Health
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07254091CT.gov Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer | — | Recruiting | — | — | — |
NCT04390399CT.gov Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT03678883CT.gov 9-ING-41 in Patients With Advanced Cancers | — | Active Not Recruiting | — | — | — |
NCT03586869CT.gov QUILT-3.080: NANT Pancreatic Cancer Vaccine | — | Terminated | — | — | — |
NCT03387098CT.gov QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | — | Terminated | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
NCT01459614CT.gov Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT01056601CT.gov Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy | — | Terminated | — | — | — |
NCT00609765CT.gov Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors | — | Terminated | — | — | — |
NCT00426127CT.gov Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer | — | Terminated | — | — | — |
Show 2 more trialsShow fewer
NCT00622674CT.gov Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00252889CT.gov Doxil Topotecan Doublet Cancer Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Northwell Health | P2 | B · 58 |
| Tinzaparin | Helsinki University Central Hospital | P4 | BBB |
| Oxaliplatin | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | BB |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Capecitabine | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Irinotecan | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Triglycerides,Medium Chain | Wei Zhou | P4 | BB |
| Desflurane | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | P4 | BB |
+42 more in the Pancreatic Neoplasm cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →